Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 2 | 6 |
| List of Tables | 6 | 1 |
| List of Figures | 7 | 1 |
| Introduction | 8 | 1 |
| Global Markets Direct Report Coverage | 8 | 1 |
| Chagas Disease (American Trypanosomiasis) Overview | 9 | 1 |
| Therapeutics Development | 10 | 2 |
| Pipeline Products for Chagas Disease (American Trypanosomiasis) Overview | 10 | 1 |
| Pipeline Products for Chagas Disease (American Trypanosomiasis) Comparative Analysis | 11 | 1 |
| Chagas Disease (American Trypanosomiasis) Therapeutics under Development by Companies | 12 | 1 |
| Chagas Disease (American Trypanosomiasis) Therapeutics under Investigation by Universities/Institutes | 13 | 1 |
| Chagas Disease (American Trypanosomiasis) Pipeline Products Glance | 14 | 3 |
| Late Stage Products | 14 | 1 |
| Clinical Stage Products | 15 | 1 |
| Early Stage Products | 16 | 1 |
| Chagas Disease (American Trypanosomiasis) Products under Development by Companies | 17 | 1 |
| Chagas Disease (American Trypanosomiasis) Products under Investigation by Universities/Institutes | 18 | 1 |
| Chagas Disease (American Trypanosomiasis) Companies Involved in Therapeutics Development | 19 | 8 |
| Bayer AG | 19 | 1 |
| Eisai Co., Ltd. | 20 | 1 |
| GlaxoSmithKline Plc | 21 | 1 |
| Grupo Praxis Pharmaceutical SA | 22 | 1 |
| KaloBios Pharmaceuticals, Inc. | 23 | 1 |
| Merck &Co., Inc. | 24 | 1 |
| Novartis AG | 25 | 1 |
| Sanofi | 26 | 1 |
| Chagas Disease (American Trypanosomiasis) Therapeutics Assessment | 27 | 9 |
| Assessment by Monotherapy Products | 27 | 1 |
| Assessment by Target | 28 | 2 |
| Assessment by Mechanism of Action | 30 | 2 |
| Assessment by Route of Administration | 32 | 2 |
| Assessment by Molecule Type | 34 | 2 |
| Drug Profiles | 36 | 36 |
| benznidazol Drug Profile | 36 | 1 |
| benznidazole Drug Profile | 37 | 1 |
| chagas disease (bivalent) vaccine Drug Profile | 38 | 1 |
| chagas disease vaccine Drug Profile | 39 | 1 |
| chagas disease vaccine Drug Profile | 40 | 1 |
| Chagas disease vaccine Drug Profile | 41 | 1 |
| Cz-007 Drug Profile | 42 | 1 |
| Cz-008 Drug Profile | 43 | 1 |
| EPLBS-1246 Drug Profile | 44 | 1 |
| EPLBS-967 Drug Profile | 45 | 1 |
| fexinidazole Drug Profile | 46 | 2 |
| fosravuconazole Drug Profile | 48 | 2 |
| GNF-6702 Drug Profile | 50 | 1 |
| K-777 Drug Profile | 51 | 2 |
| NEU-321 Drug Profile | 53 | 1 |
| nifurtimox Drug Profile | 54 | 1 |
| nifurtimox SR Drug Profile | 55 | 1 |
| posaconazole Drug Profile | 56 | 2 |
| SAR-114137 Drug Profile | 58 | 1 |
| Small Molecule to Inhibit Cruzipain for Chagas Disease Drug Profile | 59 | 1 |
| Small Molecule to Inhibit SOD for Chagas Disease and Leishmaniasis Drug Profile | 60 | 1 |
| Small Molecules for Chagas Disease Drug Profile | 61 | 1 |
| Small Molecules for Chagas Disease Drug Profile | 62 | 1 |
| Small Molecules for Chagas Disease Drug Profile | 63 | 1 |
| Small Molecules for Chagas Disease Drug Profile | 64 | 1 |
| Small Molecules for Chagas Disease Drug Profile | 65 | 1 |
| Small Molecules for Infectious Diseases Drug Profile | 66 | 1 |
| Small Molecules for Infectious Diseases Drug Profile | 67 | 1 |
| Small Molecules for Protozoal Infections Drug Profile | 68 | 1 |
| Small Molecules to Inhibit Lanosterol 14 alpha-Demethylase for Chagas Disease Drug Profile | 69 | 1 |
| Small Molecules to Inhibit Proline Racemase for Chagas Disease Drug Profile | 70 | 1 |
| VNI Drug Profile | 71 | 1 |
| Chagas Disease (American Trypanosomiasis) Dormant Projects | 72 | 1 |
| Chagas Disease (American Trypanosomiasis) Discontinued Products | 73 | 1 |
| Chagas Disease (American Trypanosomiasis) Product Development Milestones | 74 | 7 |
| Featured News &Press Releases | 74 | 1 |
| Apr 11, 2016: KaloBios Announces New Product Pricing Model | 74 | 1 |
| Jul 27, 2015: NIH helps UC San Diego researchers repurpose Sanofi pain drug for tropical disease | 74 | 1 |
| May 07, 2015: UTMB researchers devise vaccine that provides long-term protection against Chagas disease | 75 | 1 |
| Dec 26, 2013: New Drug Candidates Show Promise for Cure for Chagas Disease | 76 | 1 |
| Nov 14, 2013: Drug Trial for Leading Parasitic Killer of the Americas Shows Mixed Results but Provides New Evidence for Improved Therapy | 77 | 1 |
| May 03, 2013: Funding boost for GSK s open innovation research into diseases affecting the developing world | 78 | 1 |
| Apr 30, 2012: NYU School of Medicine Receives Support From The Tres Cantos Open Lab Foundation To Discover New Drugs Against Chagas Disease | 79 | 1 |
| Mar 12, 2012: DNDi Receives 2m Strategic Translation Award From Wellcome Trust To Develop New Drug Against Chagas Disease | 80 | 1 |
| Appendix | 81 | 2 |
| Methodology | 81 | 1 |
| Coverage | 81 | 1 |
| Secondary Research | 81 | 1 |
| Primary Research | 81 | 1 |
| Expert Panel Validation | 81 | 1 |
| Contact Us | 81 | 1 |
| Disclaimer | 82 | 1 |